Skip to content
Everfront Biotech Inc.

Everfront Biotech Inc.

  • 關於長弘
    • 創辦人的話
  • 新藥開發
    • EF-001 | 治療高度惡性腦瘤
    • EF-009 | 治療胰臟癌
  • 智慧財產
  • 最新消息
  • 聯絡我們
  • HOME 🇺🇸
  • About EFB 🇺🇸
  • Pipelines 🇺🇸
    • EF-001
    • EF-009

EN_News

EN_News 

2022-06-272022-06-27 jacky EN_News

Everfront Biotech In

Read more

EN NEWS

  • Local delivery therapy of Cerebraca® Wafer being highlighted in the natural review
    2022-06-27
  • Case report – Cerebraca® Wafer implantation combined with CIK therapy for the treatment of recurrent Glioblastoma revealed superior clinical outcome (overall survival extended for more than 24 months).
    2022-06-27
  • Case report – Cerebraca® Wafer implantation for the treatment of un-resectable cervical spine Glioblastoma resulted in the tumor regression.
    2022-06-27
  • Outstanding clinical outcomes were published in various journals. We have listed as follows:
    2022-06-27

長弘生物科技鎖定未被滿足的醫療需求。

致力開發孤兒藥，以治療世上最致命的病症。

Everfront Biotech Inc. is committed to fulfilling unmet medical needs by developing orphan drugs to treat the world’s most lethal diseases.

與我們聯絡：

  • 研發暨臨床醫學研究中心

Research, Development and Clinical Medical Research Center

  • 🏢地址：

974花蓮縣壽豐鄉大學路二段1號974國立東華大學創新育成中心1之10室

NDHU IIIC R1-10, No.1, Sec.2, Da Hsueh Rd., Shoufeng, Hualien 974, Taiwan (R.O.C.)

  • ☎電話：

+886-3-8630108

  • 📧email

efbiotech@efbiotech.com

 

  • 台北營運總部

Corporate Headquarters

  • 🏢地址：

103台北市大同區重慶北路二段178-3號2樓

2F, No.178-3, Sec.2, Chongqing N. Rd., Datong Dist., Taipei City 103 , Taiwan (R.O.C.)

  • ☎電話：
Copyright © 2023 Everfront Biotech Inc.. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.